Wolfgang Wienand to Succeed Rudolf Hanko as CEO of Siegfried

Wolfgang Wienand has been appointed as new CEO of Siegfried with effect from Jan. 1, 2019. Rudolf Hanko, the group’s current CEO, will step down on Dec. 31, 2018. The board has decided to propose the election of Hanko as a member of Siegfried’s board of directors on the occasion of the next annual general meeting in spring 2019.

Hanko (born 1955) assumed operational responsibility for Siegfried as CEO in 2009. Andreas Casutt, chairman of Siegfried: “Rudolf Hanko has had a significant effect on our company in the past nine years, and he played a decisive role in Siegfried’s continuing success. His term of office is characterized by the development of annual sales from 260 to over 700 million Swiss francs and, especially, by the targeted expansion of our production sites and the consistent orientation of our company toward meeting the fast-changing needs of pharmaceutical companies with international operations. The Board of Directors expresses its thanks to Rudolf Hanko for his great achievements on behalf of the company and is glad he will remain closely connected with Siegfried.”

Wienand (born 1972) joined Siegfried’s executive committee in 2010 and currently holds the position of Chief Scientific & Strategy Officer. Casutt commented: “The Board of Directors is pleased to appoint the new CEO from within the company. Wolfgang Wienand has made a decisive contribution toward implementation of our corporate strategy by means of successful acquisitions in recent years. He demonstrated significant leadership qualities as the person responsible for overseeing the post-merger integration of the new corporate entities and as global head of Research and Development. Thus, Wolfgang Wienand has all the prerequisites to lead our company as CEO into a successful future.”